Carlos Coto-Tejeda
Carlos Coto-Tejeda has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- César Alas-Pineda
Quantitative Biomedical Sciences Doctoral Program, Geisel School of Medicine, Dartmouth College, Hanover, NH, USA
3 shared publications - Dennis J. Pavón-Varela
Department of Research and Development, Moxie Health Group, Hallandale Beach, FL 33009, USA
3 shared publications - Gustavo Ferrer
Department of Pulmonary and Critical Care Medicine, Aventura Hospital and Medical Center, Aventura, FL 33180, USA
3 shared publications - Jhacely Medina-Mejía
Department of Research and Development, Moxie Health Group, Hallandale Beach, FL 33009, USA
3 shared publications - Kristhel Gaitán-Zambrano
Facultad de Medicina y Cirugía, Universidad Católica de Honduras - Campus San Pedro y San Pablo, San Pedro Sula, Cortés, Honduras
3 shared publications - Mark Cannon
Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
1 shared publication
Latest Publications
- Open Access
- 23 October 2026
- Published by MDPI AG in Healthcare
- Vol. 14 (21) , 3598
Pregnancy-Recognized Obstructive Sleep Apnea and Maternal–Fetal Outcomes: A Narrative Review of Gestational Rhinitis, Upper-Airway Mechanisms, and Treatment Evidence
Background/Objectives: Pregnancy-recognized obstructive sleep apnea (POSA) is an operational construct, not a validated biological phenotype, and remains underrecognized in prenatal care. This review synthesizes evidence on POSA-related outcomes, evaluates gestational rhinitis as a candidate contributor to upper-airway vulnerability, and distinguishes pregnancy safety from demonstrated efficacy for OSA-related endpoints. Methods: This structured narrative review, informed by SANRA criteria, used a structured PubMed search (7 March 2026) with targeted supplementary searches through 9 October 2026, across six predefined domains. Results: Pregnancy-recognized OSA is associated in observational studies with hypertensive disorders, preterm birth, impaired fetal growth (in small pregnancy-specific studies), and severe maternal morbidity; residual confounding by obesity precludes causal inference. In a 2024 meta-analysis of randomized and observational studies (n = 809), continuous positive airway pressure (CPAP) was associated with lower risks of gestational hypertension (RR, 0.65; 95% CI, 0.47–0.89) and preeclampsia (RR, 0.70; 95% CI, 0.50–0.98). Although secondary endpoints in individual trials suggested benefit, the pooled preeclampsia effect was fragile in sensitivity and subgroup analyses. Gestational rhinitis affects approximately one in five pregnant women and is a plausible but untested contributor to pregnancy-recognized OSA. Saline irrigation, budesonide (mainly inhaled-exposure data), and chlorpheniramine have gestational safety data, but the only randomized trial of an intranasal corticosteroid in gestational rhinitis was null, and we identified no study of OSA endpoints. Conclusions: Given the largely observational evidence, objective testing and individualized treatment may be considered in high-risk patients, pending adequately powered trials. CPAP is the standard treatment for objectively confirmed OSA.
- 23 October 2026
- Published by MDPI AG in Healthcare
- Vol. 14 (21) , 3598
Open AccessPregnancy-Recognized Obstructive Sleep Apnea and Maternal–Fetal Outcomes: A Narrative Review of Gestational Rhinitis, Upper-Airway Mechanisms, and Treatment Evidence
Background/Objectives: Pregnancy-recognized obstructive sleep apnea (POSA) is an operational construct, not a validated biological phenotype, and remains underrecognized in prenatal care. This review synthesizes evidence on POSA-related outcomes, evaluates gestational rhinitis as a candidate contributor to upper-airway vulnerability, and distinguishes pregnancy safety from demonstrated efficacy for OSA-related endpoints. Methods: This structured narrative review, informed by SANRA criteria, used a structured PubMed search (7 March 2026) with targeted supplementary searches through 9 October 2026, across six predefined domains. Results: Pregnancy-recognized OSA is associated in observational studies with hypertensive disorders, preterm birth, impaired fetal growth (in small pregnancy-specific studies), and severe maternal morbidity; residual confounding by obesity precludes causal inference. In a 2024 meta-analysis of randomized and observational studies (n = 809), continuous positive airway pressure (CPAP) was associated with lower risks of gestational hypertension (RR, 0.65; 95% CI, 0.47–0.89) and preeclampsia (RR, 0.70; 95% CI, 0.50–0.98). Although secondary endpoints in individual trials suggested benefit, the pooled preeclampsia effect was fragile in sensitivity and subgroup analyses. Gestational rhinitis affects approximately one in five pregnant women and is a plausible but untested contributor to pregnancy-recognized OSA. Saline irrigation, budesonide (mainly inhaled-exposure data), and chlorpheniramine have gestational safety data, but the only randomized trial of an intranasal corticosteroid in gestational rhinitis was null, and we identified no study of OSA endpoints. Conclusions: Given the largely observational evidence, objective testing and individualized treatment may be considered in high-risk patients, pending adequately powered trials. CPAP is the standard treatment for objectively confirmed OSA.
- Open Access
- 8 September 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (9) , 1128
Human Factors and Device Engineering in OTC Intranasal Drug Delivery: GentleMist Technology™
Intranasal drug delivery is noninvasive, rapid-acting, and well suited to self-administration, yet the real-world performance of nasal sprays depends on the interaction among formulation, device mechanics, nasal anatomy, and user technique rather than on the active ingredient alone. This narrative review examines how aerosol science, regional targeting, and human factors jointly shape intranasal performance, using GentleMist Technology™ as a representative example of emerging device-centered development. Computational fluid dynamics (CFD) and anatomically informed in vitro models indicate that device geometry, plume characteristics, and administration angle can significantly alter where a dose is deposited, while human factors research identifies priming, positioning, and angulation as key determinants of successful over-the-counter (OTC) use. We summarize early feasibility data suggesting that angle-optimized administration may increase posterior nasopharyngeal delivery and that essential tasks are feasible for lay users, with priming emerging as a specific usability vulnerability. We also review preliminary clinical evidence on a chlorpheniramine maleate (CPM)-based intranasal formulation in allergic rhinitis and viral upper respiratory illness. Although the strongest device-specific findings remain preliminary and require independent replication, they support an emerging shift from a formulation-centered model toward an integrated device–formulation–user paradigm.
- 8 September 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (9) , 1128
Open AccessHuman Factors and Device Engineering in OTC Intranasal Drug Delivery: GentleMist Technology™
Intranasal drug delivery is noninvasive, rapid-acting, and well suited to self-administration, yet the real-world performance of nasal sprays depends on the interaction among formulation, device mechanics, nasal anatomy, and user technique rather than on the active ingredient alone. This narrative review examines how aerosol science, regional targeting, and human factors jointly shape intranasal performance, using GentleMist Technology™ as a representative example of emerging device-centered development. Computational fluid dynamics (CFD) and anatomically informed in vitro models indicate that device geometry, plume characteristics, and administration angle can significantly alter where a dose is deposited, while human factors research identifies priming, positioning, and angulation as key determinants of successful over-the-counter (OTC) use. We summarize early feasibility data suggesting that angle-optimized administration may increase posterior nasopharyngeal delivery and that essential tasks are feasible for lay users, with priming emerging as a specific usability vulnerability. We also review preliminary clinical evidence on a chlorpheniramine maleate (CPM)-based intranasal formulation in allergic rhinitis and viral upper respiratory illness. Although the strongest device-specific findings remain preliminary and require independent replication, they support an emerging shift from a formulation-centered model toward an integrated device–formulation–user paradigm.
- Open Access
- 19 May 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (5) , 796
New Technique for Tramadol Dose Accuracy: Are Dosing Pumps the Solution?
Background/Objectives: Chronic pain represents a core global health burden and remains a leading cause of disability and reduced quality of life. Tramadol is a widely prescribed analgesic with a dual-opioid and non-opioid mechanism of action; however, safety concerns persist. This scoping review summarizes current evidence on tramadol pharmacology, dosing, and safety. Methods: A systematic literature search was conducted across main scientific databases to identify preclinical and clinical studies evaluating tramadol pharmacokinetics, safety, and dosing. Results: The same tramadol presentations have been used for several years, with a high overdose risk due to incorrect dosing measurements. Dosing pump devices represent a viable solution to improve dosing accuracy and minimize this risk. Conclusions: Tramadol drops seem like an easier administration pathway but require careful handling when taking the prescribed dose. A dosing pump in the medication bottle will improve dosing accuracy.
- 19 May 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (5) , 796
Open AccessNew Technique for Tramadol Dose Accuracy: Are Dosing Pumps the Solution?
Background/Objectives: Chronic pain represents a core global health burden and remains a leading cause of disability and reduced quality of life. Tramadol is a widely prescribed analgesic with a dual-opioid and non-opioid mechanism of action; however, safety concerns persist. This scoping review summarizes current evidence on tramadol pharmacology, dosing, and safety. Methods: A systematic literature search was conducted across main scientific databases to identify preclinical and clinical studies evaluating tramadol pharmacokinetics, safety, and dosing. Results: The same tramadol presentations have been used for several years, with a high overdose risk due to incorrect dosing measurements. Dosing pump devices represent a viable solution to improve dosing accuracy and minimize this risk. Conclusions: Tramadol drops seem like an easier administration pathway but require careful handling when taking the prescribed dose. A dosing pump in the medication bottle will improve dosing accuracy.